Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 769 entries
Sorted by: Best Match Show Resources per page
Endoscopic ultrasound-guided biliary drainage: an update.

Current treatment options in gastroenterology

Kumta NA, Kedia P, Kahaleh M.
PMID: 24623591
Curr Treat Options Gastroenterol. 2014 Jun;12(2):154-68. doi: 10.1007/s11938-014-0011-1.

OPINION STATEMENT: Endoscopic retrograde cholangiopancreatography (ERCP) is currently the preferred procedure for biliary drainage in both benign and malignant obstructions. While ERCP is successful in approximately 95 % of cases, a small subset of cases are unsuccessful due to...

Cite
Kumta NA, Kedia P, Kahaleh M. Endoscopic ultrasound-guided biliary drainage: an update. Curr Treat Options Gastroenterol. 2014;12(2):154-68doi: 10.1007/s11938-014-0011-1.
Kumta, N. A., Kedia, P., & Kahaleh, M. (2014). Endoscopic ultrasound-guided biliary drainage: an update. Current treatment options in gastroenterology, 12(2), 154-68. https://doi.org/10.1007/s11938-014-0011-1
Kumta, Nikhil A, et al. "Endoscopic ultrasound-guided biliary drainage: an update." Current treatment options in gastroenterology vol. 12,2 (2014): 154-68. doi: https://doi.org/10.1007/s11938-014-0011-1
Kumta NA, Kedia P, Kahaleh M. Endoscopic ultrasound-guided biliary drainage: an update. Curr Treat Options Gastroenterol. 2014 Jun;12(2):154-68. doi: 10.1007/s11938-014-0011-1. PMID: 24623591.
Copy Download .nbib Format: NLM
Sedation in the Endoscopy Suite.

Current treatment options in gastroenterology

Hagan KB, Thirumurthi S, Gottumukkala R, Vargo J.
PMID: 27000038
Curr Treat Options Gastroenterol. 2016 Jun;14(2):194-209. doi: 10.1007/s11938-016-0089-8.

OPINION STATEMENT: Sedation practices in the endoscopy suite have changed dramatically in the decades since the introduction of routine colonoscopy and esophagogastroduodenoscopy (EGD). Patients initially received moderate sedation (or even no sedation), but now frequently receive monitored anesthesia care...

Cite
Hagan KB, Thirumurthi S, Gottumukkala R, et al. Sedation in the Endoscopy Suite. Curr Treat Options Gastroenterol. 2016;14(2):194-209doi: 10.1007/s11938-016-0089-8.
Hagan, K. B., Thirumurthi, S., Gottumukkala, R., & Vargo, J. (2016). Sedation in the Endoscopy Suite. Current treatment options in gastroenterology, 14(2), 194-209. https://doi.org/10.1007/s11938-016-0089-8
Hagan, Katherine B, et al. "Sedation in the Endoscopy Suite." Current treatment options in gastroenterology vol. 14,2 (2016): 194-209. doi: https://doi.org/10.1007/s11938-016-0089-8
Hagan KB, Thirumurthi S, Gottumukkala R, Vargo J. Sedation in the Endoscopy Suite. Curr Treat Options Gastroenterol. 2016 Jun;14(2):194-209. doi: 10.1007/s11938-016-0089-8. PMID: 27000038.
Copy Download .nbib Format: NLM
Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.

Current treatment options in gastroenterology

Rich NE, Parikh ND, Singal AG.
PMID: 28425018
Curr Treat Options Gastroenterol. 2017 Jun;15(2):296-304. doi: 10.1007/s11938-017-0133-3.

OPINION STATEMENT: Benefits of liver transplantation (LT) for patients with hepatocellular carcinoma (HCC) are well established. However, there is debate regarding optimal and equitable selection of patients best served by LT, particularly in the face of limited organ availability....

Cite
Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastroenterol. 2017;15(2):296-304doi: 10.1007/s11938-017-0133-3.
Rich, N. E., Parikh, N. D., & Singal, A. G. (2017). Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Current treatment options in gastroenterology, 15(2), 296-304. https://doi.org/10.1007/s11938-017-0133-3
Rich, Nicole E, et al. "Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices." Current treatment options in gastroenterology vol. 15,2 (2017): 296-304. doi: https://doi.org/10.1007/s11938-017-0133-3
Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastroenterol. 2017 Jun;15(2):296-304. doi: 10.1007/s11938-017-0133-3. PMID: 28425018.
Copy Download .nbib Format: NLM
Update on the Diagnosis and Management of Colon Ischemia.

Current treatment options in gastroenterology

Flynn AD, Valentine JF.
PMID: 26815145
Curr Treat Options Gastroenterol. 2016 Mar;14(1):128-39. doi: 10.1007/s11938-016-0074-2.

OPINION STATEMENT: Colonic ischemia is the most common ischemic disorder of the gastrointestinal tract. The condition occurs more commonly in women, and risk increases with advancing age. Presenting symptoms include abdominal pain, bowel urgency, and passage of bloody diarrhea;...

Cite
Flynn AD, Valentine JF. Update on the Diagnosis and Management of Colon Ischemia. Curr Treat Options Gastroenterol. 2016;14(1):128-39doi: 10.1007/s11938-016-0074-2.
Flynn, A. D., & Valentine, J. F. (2016). Update on the Diagnosis and Management of Colon Ischemia. Current treatment options in gastroenterology, 14(1), 128-39. https://doi.org/10.1007/s11938-016-0074-2
Flynn, Ann D, and Valentine, John F. "Update on the Diagnosis and Management of Colon Ischemia." Current treatment options in gastroenterology vol. 14,1 (2016): 128-39. doi: https://doi.org/10.1007/s11938-016-0074-2
Flynn AD, Valentine JF. Update on the Diagnosis and Management of Colon Ischemia. Curr Treat Options Gastroenterol. 2016 Mar;14(1):128-39. doi: 10.1007/s11938-016-0074-2. PMID: 26815145.
Copy Download .nbib Format: NLM
Management of Disconnected Pancreatic Duct Syndrome.

Current treatment options in gastroenterology

Larsen M, Kozarek RA.
PMID: 27392638
Curr Treat Options Gastroenterol. 2016 Sep;14(3):348-59. doi: 10.1007/s11938-016-0098-7.

OPINION STATEMENT: A disconnected pancreatic duct most commonly follows an episode of severe pancreatitis and walled-off necrosis (WON). When the latter is drained percutaneously, a pancreatic fistula connected to an upstream and disconnected duct is commonly seen. Transgastric drainage...

Cite
Larsen M, Kozarek RA. Management of Disconnected Pancreatic Duct Syndrome. Curr Treat Options Gastroenterol. 2016;14(3):348-59doi: 10.1007/s11938-016-0098-7.
Larsen, M., & Kozarek, R. A. (2016). Management of Disconnected Pancreatic Duct Syndrome. Current treatment options in gastroenterology, 14(3), 348-59. https://doi.org/10.1007/s11938-016-0098-7
Larsen, Michael, and Kozarek, Richard A. "Management of Disconnected Pancreatic Duct Syndrome." Current treatment options in gastroenterology vol. 14,3 (2016): 348-59. doi: https://doi.org/10.1007/s11938-016-0098-7
Larsen M, Kozarek RA. Management of Disconnected Pancreatic Duct Syndrome. Curr Treat Options Gastroenterol. 2016 Sep;14(3):348-59. doi: 10.1007/s11938-016-0098-7. PMID: 27392638.
Copy Download .nbib Format: NLM
Endoscopic Evaluation/Management of Bariatric Surgery Complications.

Current treatment options in gastroenterology

Schulman AR, Thompson CC.
PMID: 29127551
Curr Treat Options Gastroenterol. 2017 Dec;15(4):701-716. doi: 10.1007/s11938-017-0164-9.

OPINION STATEMENT: Purpose of Review Bariatric surgery has become increasingly common given the increasing prevalence of obesity and its associated co-morbidities. As a result, patients who have surgically altered anatomy will be seen with increasing frequency by gastroenterologists. Recent...

Cite
Schulman AR, Thompson CC. Endoscopic Evaluation/Management of Bariatric Surgery Complications. Curr Treat Options Gastroenterol. 2017;15(4):701-716doi: 10.1007/s11938-017-0164-9.
Schulman, A. R., & Thompson, C. C. (2017). Endoscopic Evaluation/Management of Bariatric Surgery Complications. Current treatment options in gastroenterology, 15(4), 701-716. https://doi.org/10.1007/s11938-017-0164-9
Schulman, Allison R, and Thompson, Christopher C. "Endoscopic Evaluation/Management of Bariatric Surgery Complications." Current treatment options in gastroenterology vol. 15,4 (2017): 701-716. doi: https://doi.org/10.1007/s11938-017-0164-9
Schulman AR, Thompson CC. Endoscopic Evaluation/Management of Bariatric Surgery Complications. Curr Treat Options Gastroenterol. 2017 Dec;15(4):701-716. doi: 10.1007/s11938-017-0164-9. PMID: 29127551.
Copy Download .nbib Format: NLM
Gastric Peroral Endoscopic Pyloromyotomy Therapy for Refractory Gastroparesis.

Current treatment options in gastroenterology

Benias PC, Khashab MA.
PMID: 29030799
Curr Treat Options Gastroenterol. 2017 Dec;15(4):637-647. doi: 10.1007/s11938-017-0156-9.

OPINION STATEMENT: Purpose of review Gastroparesis is a complex dysmotility disorder in which a number of normal gastric emptying mechanisms can be affected. The pylorus as an apparatus is particularly important since it stands as the last final gateway...

Cite
Benias PC, Khashab MA. Gastric Peroral Endoscopic Pyloromyotomy Therapy for Refractory Gastroparesis. Curr Treat Options Gastroenterol. 2017;15(4):637-647doi: 10.1007/s11938-017-0156-9.
Benias, P. C., & Khashab, M. A. (2017). Gastric Peroral Endoscopic Pyloromyotomy Therapy for Refractory Gastroparesis. Current treatment options in gastroenterology, 15(4), 637-647. https://doi.org/10.1007/s11938-017-0156-9
Benias, Petros C, and Khashab, Mouen A. "Gastric Peroral Endoscopic Pyloromyotomy Therapy for Refractory Gastroparesis." Current treatment options in gastroenterology vol. 15,4 (2017): 637-647. doi: https://doi.org/10.1007/s11938-017-0156-9
Benias PC, Khashab MA. Gastric Peroral Endoscopic Pyloromyotomy Therapy for Refractory Gastroparesis. Curr Treat Options Gastroenterol. 2017 Dec;15(4):637-647. doi: 10.1007/s11938-017-0156-9. PMID: 29030799.
Copy Download .nbib Format: NLM
Role of Nutrition and Muscle in Cirrhosis.

Current treatment options in gastroenterology

Thandassery RB, Montano-Loza AJ.
PMID: 27023701
Curr Treat Options Gastroenterol. 2016 Jun;14(2):257-73. doi: 10.1007/s11938-016-0093-z.

OPINION STATEMENT: Most widely recognized complications in cirrhotic patients include ascites, hepatic encephalopathy, variceal bleeding, kidney dysfunction, and hepatocellular carcinoma; however, malnutrition and muscle wasting (sarcopenia) constitute common complications which negatively impact survival, quality of life, and response to...

Cite
Thandassery RB, Montano-Loza AJ. Role of Nutrition and Muscle in Cirrhosis. Curr Treat Options Gastroenterol. 2016;14(2):257-73doi: 10.1007/s11938-016-0093-z.
Thandassery, R. B., & Montano-Loza, A. J. (2016). Role of Nutrition and Muscle in Cirrhosis. Current treatment options in gastroenterology, 14(2), 257-73. https://doi.org/10.1007/s11938-016-0093-z
Thandassery, Ragesh B, and Montano-Loza, Aldo J. "Role of Nutrition and Muscle in Cirrhosis." Current treatment options in gastroenterology vol. 14,2 (2016): 257-73. doi: https://doi.org/10.1007/s11938-016-0093-z
Thandassery RB, Montano-Loza AJ. Role of Nutrition and Muscle in Cirrhosis. Curr Treat Options Gastroenterol. 2016 Jun;14(2):257-73. doi: 10.1007/s11938-016-0093-z. PMID: 27023701.
Copy Download .nbib Format: NLM
Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis.

Current treatment options in gastroenterology

Harer KN, Pasricha PJ.
PMID: 27722801
Curr Treat Options Gastroenterol. 2016 Dec;14(4):410-419. doi: 10.1007/s11938-016-0113-z.

OPINION STATEMENT: Chronic unexplained nausea and vomiting is a debilitating condition that dramatically decreases patient quality of life and creates diagnostic and treatment challenges for healthcare providers. Additionally, the significant overlap in symptoms between disorders such as chronic unexplained...

Cite
Harer KN, Pasricha PJ. Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis. Curr Treat Options Gastroenterol. 2016;14(4):410-419doi: 10.1007/s11938-016-0113-z.
Harer, K. N., & Pasricha, P. J. (2016). Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis. Current treatment options in gastroenterology, 14(4), 410-419. https://doi.org/10.1007/s11938-016-0113-z
Harer, Kimberly N, and Pasricha, Pankaj J. "Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis." Current treatment options in gastroenterology vol. 14,4 (2016): 410-419. doi: https://doi.org/10.1007/s11938-016-0113-z
Harer KN, Pasricha PJ. Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis. Curr Treat Options Gastroenterol. 2016 Dec;14(4):410-419. doi: 10.1007/s11938-016-0113-z. PMID: 27722801; PMCID: PMC5102760.
Copy Download .nbib Format: NLM
Current and Emerging Medical Therapies for Gastroparesis.

Current treatment options in gastroenterology

Zhao X, Mashimo H.
PMID: 26507073
Curr Treat Options Gastroenterol. 2015 Dec;13(4):452-72. doi: 10.1007/s11938-015-0071-x.

OPINION STATEMENT: Gastroparesis likely involves various pathophysiological disorders and is increasingly prevalent as complications of surgeries, medications, and chronic diabetes. Key to diagnosis is evidence of delayed gastric emptying, generally based on standardized scintigraphy, and ruling out distal obstruction...

Cite
Zhao X, Mashimo H. Current and Emerging Medical Therapies for Gastroparesis. Curr Treat Options Gastroenterol. 2015;13(4):452-72doi: 10.1007/s11938-015-0071-x.
Zhao, X., & Mashimo, H. (2015). Current and Emerging Medical Therapies for Gastroparesis. Current treatment options in gastroenterology, 13(4), 452-72. https://doi.org/10.1007/s11938-015-0071-x
Zhao, Xiaofeng, and Mashimo, Hiroshi. "Current and Emerging Medical Therapies for Gastroparesis." Current treatment options in gastroenterology vol. 13,4 (2015): 452-72. doi: https://doi.org/10.1007/s11938-015-0071-x
Zhao X, Mashimo H. Current and Emerging Medical Therapies for Gastroparesis. Curr Treat Options Gastroenterol. 2015 Dec;13(4):452-72. doi: 10.1007/s11938-015-0071-x. PMID: 26507073.
Copy Download .nbib Format: NLM
Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice.

Current treatment options in gastroenterology

Cheng E.
PMID: 25598233
Curr Treat Options Gastroenterol. 2015 Mar;13(1):30-46. doi: 10.1007/s11938-014-0041-8.

OPINION STATEMENT: New developments in eosinophilic esophagitis (EoE) pathogenesis are shaping our current therapeutic and management strategies. EoE is a chronic allergic inflammatory disease with progression to fibrostenotic disease. The disease warrants early diagnosis and long-term maintenance therapy. The...

Cite
Cheng E. Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice. Curr Treat Options Gastroenterol. 2015;13(1):30-46doi: 10.1007/s11938-014-0041-8.
Cheng, E. (2015). Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice. Current treatment options in gastroenterology, 13(1), 30-46. https://doi.org/10.1007/s11938-014-0041-8
Cheng, Edaire. "Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice." Current treatment options in gastroenterology vol. 13,1 (2015): 30-46. doi: https://doi.org/10.1007/s11938-014-0041-8
Cheng E. Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice. Curr Treat Options Gastroenterol. 2015 Mar;13(1):30-46. doi: 10.1007/s11938-014-0041-8. PMID: 25598233; PMCID: PMC4329259.
Copy Download .nbib Format: NLM
Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.

Current treatment options in gastroenterology

Leung G, Papademetriou M, Chang S, Arena F, Katz S.
PMID: 27709332
Curr Treat Options Gastroenterol. 2016 Dec;14(4):507-534. doi: 10.1007/s11938-016-0109-8.

OPINION STATEMENT: As new and effective novel therapies in inflammatory bowel disease (IBD) become available, patients are living longer with advancing age and are at increased risk for malignancy. The management of IBD and malignancy involves multiple combinations of...

Cite
Leung G, Papademetriou M, Chang S, et al. Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. Curr Treat Options Gastroenterol. 2016;14(4):507-534doi: 10.1007/s11938-016-0109-8.
Leung, G., Papademetriou, M., Chang, S., Arena, F., & Katz, S. (2016). Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. Current treatment options in gastroenterology, 14(4), 507-534. https://doi.org/10.1007/s11938-016-0109-8
Leung, Galen, et al. "Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy." Current treatment options in gastroenterology vol. 14,4 (2016): 507-534. doi: https://doi.org/10.1007/s11938-016-0109-8
Leung G, Papademetriou M, Chang S, Arena F, Katz S. Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. Curr Treat Options Gastroenterol. 2016 Dec;14(4):507-534. doi: 10.1007/s11938-016-0109-8. PMID: 27709332.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 769 entries